Compare CMT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMT | ALXO |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | 1239 | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.8M | 205.9M |
| IPO Year | 1996 | 2020 |
| Metric | CMT | ALXO |
|---|---|---|
| Price | $23.89 | $2.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $24.00 | $3.50 |
| AVG Volume (30 Days) | 19.5K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $284,290,000.00 | N/A |
| Revenue This Year | $4.58 | N/A |
| Revenue Next Year | $6.04 | N/A |
| P/E Ratio | $89.48 | ★ N/A |
| Revenue Growth | ★ 5.49 | N/A |
| 52 Week Low | $16.60 | $1.02 |
| 52 Week High | $28.69 | $2.66 |
| Indicator | CMT | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 50.29 |
| Support Level | $22.80 | $1.90 |
| Resistance Level | $25.38 | $2.17 |
| Average True Range (ATR) | 1.10 | 0.10 |
| MACD | -0.22 | -0.00 |
| Stochastic Oscillator | 26.38 | 45.83 |
Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.